���沙莫瑞林历史与监管定位 — Questions and Answers

By Editorial Desk · published 2026-08-01 · last reviewed 2026-08-01 · News

The short version of Visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

特沙莫瑞林历史与监管定位

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

Mechanism and Pharmacodynamics

Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.

Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.

Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Related pages on this site

• Technical checklist
• Structured archive
• Portable primer
• Practical summary
• Reliable overview
• Modular handbook
• Portable checklist
• Robust notes

Mechanism And Pharmacodynamic Markers

Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.

Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.

Background And Regulatory Development

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Mechanism and Research Endpoints

Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.

Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.

Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.

Notes from published material

== Early life == Michael Heseltine was born at Eaton Crescent, in Swansea in Wales on 21 March 1933. He was the son of Territorial Army Colonel Rupert Dibdin Heseltine (1902–1957), TD, of the Royal Engineers during the Second World War, a factory owner and South Wales local director of Dawnays Ltd, bridge and structural engineers, and Eileen Ray (née Pridmore). The Heseltine family were in the tea trade: Michael Heseltine's great-grandfather, William Heseltine, was a clerk who worked his way up to being manager of Tetley, later being involved in establishing a chain of grocers; he killed himself after suffering the loss of his fortune through debt and bad investments. Michael Heseltine's grandfather, John William Dibdin Heseltine (whose mother was a great-granddaughter of the composer and songwriter Charles Dibdin), became a tea salesman and relocated from Huntingdonshire to Swansea, the docks being a major arrival point for tea shipments. Earlier generations had been farm labourers in Pembrey. Heseltine's mother originated in West Wales, daughter of James Pridmore, a dock labourer who unloaded coal from ships, later hiring others to do so and founding West Glamorgan Collieries Ltd, a short-lived company that briefly worked two small mines on the outskirts of Swansea (1919–1921); his father, also James, worked at the Swansea docks. Due to this heritage Heseltine was later made an honorary member of the Swansea Dockers Club. Heseltine was brought up in relative luxury at No. 1, Eaton Crescent, Swansea (now No. 5).

The signs and symptoms of ankylosing spondylitis often appear gradually, with peak onset between 20 and 30 years of age. Initial symptoms are usually a chronic dull pain in the lower back or gluteal region combined with stiffness of the lower back. Individuals often experience pain and stiffness that awakens them in the early morning hours. As the disease progresses, loss of spinal mobility and chest expansion, with a limitation of anterior flexion, lateral flexion, and extension of the lumbar spine are seen. Systemic features are common with weight loss, fever, or fatigue often present. Pain is often severe at rest but may improve with physical activity. Inflammation and pain may recur to varying degrees regardless of rest and movement. AS can occur in any part of the spine or the entire spine, often with pain localized to either buttock or the back of the thigh from the sacroiliac joint. Arthritis in the hips and shoulders may also occur. When the condition presents before the age of 18, AS is more likely to cause pain and swelling of large lower limb joints, such as the knees. In prepubescent cases, pain and swelling may also manifest in the ankles and feet, where heel pain and enthesopathy commonly develop. Less common occurrences include ectasia of the sacral nerve root sheaths. About 30% of people with AS will also experience anterior uveitis, causing eye pain, redness, and blurred vision. This is thought to be due to the association that both AS and uveitis have with the presence of the HLA-B27 antigen.

Generalmajor Walter Hörnlein - 1 April 1942 – 3 April 1943 Generalleutnant Hermann Balck - 3 April - 30 June 1943 Generalleutnant Walter Hörnlein - 30 June 1943 - 1 February 1944 Generalleutnant Hasso von Manteuffel - 1 February 1944 – August 1944 Generalmajor Karl Lorenz - 1 September 1944 - 7 May 1945

Howard Walter Florey, Baron Florey of Adelaide and Marston (; 24 September 1898 – 21 February 1968) was an Australian pharmacologist and pathologist who shared the Nobel Prize in Physiology or Medicine in 1945 with Ernst Chain and Sir Alexander Fleming "for the discovery of penicillin and its curative effect in various infectious diseases". Although Fleming received most of the credit for the discovery of penicillin, it was Florey and his team at the University of Oxford who made it into a useful and effective drug, ten years after Fleming had abandoned its development. They developed techniques for growing, purifying and manufacturing the drug, tested it for toxicity and efficacy on animals, and carried out the first clinical trials. In 1941, they used it to treat a police constable from Oxford. He started to recover, but subsequently died because Florey was unable, at that time, to make enough penicillin. Later trials in Britain, the United States and North Africa were highly successful. A graduate of the University of Adelaide, Florey studied at the University of Oxford as a Rhodes Scholar and in the United States on a fellowship from the Rockefeller Foundation. In 1935, he became the director of the Sir William Dunn School of Pathology at Oxford. He assembled a multidisciplinary staff that could tackle major research projects. In addition to his work on penicillin, he researched many other subjects, most notably lysozyme, contraception and cephalosporins.

Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.

Sources: en.wikipedia.org

Further detail

Stimulants enhance the activity of the central and peripheral nervous systems. Common effects may include increased alertness, awareness, wakefulness, endurance, productivity and motivation, arousal, locomotion, heart rate and blood pressure, and a diminished desire for food and sleep. Use of stimulants may cause the body to reduce significantly its production of natural body chemicals that fulfill similar functions. Until the body reestablishes its normal state, once the effect of the ingested stimulant has worn off the user may feel depressed, lethargic, confused, and miserable. This state is referred to as a "crash", and may provoke reuse of the stimulant. Abuse of central nervous system (CNS) stimulants is common. Addiction to some CNS stimulants can quickly lead to medical, psychiatric, and psychosocial deterioration. Drug tolerance, dependence, and sensitization as well as a withdrawal syndrome can occur. Stimulants may be screened for in animal discrimination and self-administration models which have high sensitivity albeit low specificity. Research on a progressive ratio self-administration protocol has found amphetamine, methylphenidate, modafinil, cocaine, and nicotine to all have a higher break point than placebo that scales with dose indicating reinforcing effects. A progressive ratio self-administration protocol is a way of testing how much an animal or a human wants a drug by making them do a certain action (like pressing a lever or poking a nose device) to get the drug.

1969), former editor of The Times; former director of BBC News; co-founder of Tortoise Media, news website co-founded with Matthew Barzun, a former U.S. Ambassador to the United Kingdom, which purchased The Observer in 2024 with the transfer taking place on 22 April 2025. Lee Harpin, ( b. 1967 ) In the late 1980s, Harpin regularly wrote for the iconic British style, music, and fashion magazines The Face and i-D; has also written for Daily Star, News of the World, Sunday People, Sunday Mirror, Daily Mirror, Mail on Sunday and Daily Mail, Jewish Chronicle, Political Editor at The Jewish News , Times of Israel, United with Israel ( UWI ). Ernest Abraham Hart Simon Hattenstone (born 29 December 1962 in Salford, England); journalist and writer; features writer and interviewer for The Guardian. He has also written or ghost-written a number of biographical books. Afua Hirsch (born 1981); of Ghanaian and German Jewish paternal lineage; has worked as a journalist for The Guardian newspaper, and Education Editor for Sky News; author of Brit(ish): On Race, Identity and Belonging; was on panel of judges for Booker Prize for Fiction; was included in 2020 edition of the Powerlist of the most influential Britons from African/African-Caribbean heritage; was cited as one of top 100 most influential Africans by New African; in Powerlist 2021, she made top 10, ranking ninth most influential person of African or African Caribbean heritage in United Kingdom; Hirsh is great-niece of noted scholar Peter Hirsch.

After the wound debridement, adequate dressings should be applied to promote wound healing. Wounds are generally packed with wet-to-dry dressings and left open to heal. In certain cases, vacuum-sealing drainage (VSD) may help the wound heal, especially in Fournier gangrene. For necrotizing infection of the perineal area (Fournier's gangrene), wound debridement and care in this area can be difficult because of the excretory products that often render the area dirty and negatively affect wound healing. Therefore, regular dressing changes with a fecal management system can help to keep the wound in the perineal area clean. Sometimes, colostomy may be necessary to divert the excretory products to keep the wound in the perineal area clean.

== Modern culture == In Richard Wagner's 1882 opera Parsifal, loosely based on Wolfram von Eschenbach's epic poem Parzifal, Amfortas, King of the Grail Knights, is the Fisher King figure who suffers an unhealable wound. The 1922 poem The Waste Land by T. S. Eliot loosely follows the legend of the Fisher King. In the 1945 novel That Hideous Strength by C. S. Lewis, the third book of The Space Trilogy, the philologist Elwin Ransom is, among other roles, the Fisher King. The 1952 novel The Natural by Bernard Malamud (and the 1984 movie) are structured around the basic legend. Pop Fisher is the Fisher King and Roy Hobbs the Percival figure. The 1974 book He: Understanding Masculine Psychology by Robert A. Johnson uses the myth of the Fisher King and Parsifal to explain masculine psychology using Jungian psychological concepts. In Tim Powers' 1979 novel The Drawing of the Dark, the Fisher King is the driving force behind the major plot, and his 1992 novel Last Call relates the Fisher King legend to the Tarot and viticulture, among other things. The 1981 film Excalibur by John Boorman largely bases its version of the Grail Quest upon the mythological pattern of the Fisher King tale, with its wounded Arthur wasting away and Percival healing him by discovering the truth of the Grail mystery. The 1984 comic series Mage: The Hero Discovered revolves around Kevin Matchstick, a character charged with protecting the mysterious Fisher King, as he is the modern Arthur. The second movement of the 1985 orchestral piece Harmonielehre by John Adams is titled The Anfortas Wound.

Sources: en.wikipedia.org

Background from the literature

=== Limitations === Proteolysis does not always yield a set of readily analyzable peptides covering the entire sequence of POI. The fragmentation of peptides in the mass spectrometer often does not yield ions corresponding to cleavage at each peptide bond. Thus, the deduced sequence for each peptide is not necessarily complete. The standard methods of fragmentation do not distinguish between leucine and isoleucine residues since they are isomeric. Because the Edman degradation proceeds from the N-terminus of the protein, it will not work if the N-terminus has been chemically modified (e.g. by acetylation or formation of Pyroglutamic acid). Edman degradation is generally not useful to determine the positions of disulfide bridges. It also requires peptide amounts of 1 picomole or above for discernible results, making it less sensitive than mass spectrometry.

Electrosmog is colloquially understood as the exposure of humans and the environment to electric, magnetic and electromagnetic fields, some of which are believed to have undesirable biological effects. Electromagnetic environmental compatibility (EMC) refers to the effects on living organisms, some of which are considered electrosensitive. Fears of such effects have existed since the beginning of technological use in the mid-19th century. In 1890, for example, officials of the Royal General Directorate in Bavaria were forbidden to attend the opening ceremony of Germany's first alternating current power plant, the Reichenhall Electricity Works, or to enter the machine room. With the establishment of the first radio telegraphy and its telegraph stations, the U.S. magazine The Atlanta Constitution reported in April 1911 on the potential dangers of radio telegraph waves, which, in addition to "tooth loss," were said to cause hair loss and make people "crazy" over time. Full-body protection was recommended as a preventive measure. During the second half of the 20th century, other sources of electromagnetic fields have become the focus of health concerns, such as power lines, photovoltaic systems, microwave ovens, computer and television screens, security devices, radar equipment, and more recently, cordless telephones (DECT), cell phones, their base stations, energy-saving lamps, and Bluetooth connections. Electrified railroad lines, tram overhead lines and subway tracks are also strong sources of electrosmog.

==== Edwards v. Aguillard ==== Following the McLean ruling, which declared the teaching of "creation science" in public schools to be an unconstitutional establishment of religion, Louisiana's version of the "Equal Time" legislation was put to the test. This time, Wendell Bird was deputized by the state and ran the state's defense of the law. Dean Kenyon was advertised as the creationists' lead expert witness, however the case (which eventually became Edwards v. Aguillard when it reached the Supreme Court) was decided by summary judgment, and so never went to a full trial. Nevertheless, in written briefs and in his oral arguments, Bird relied heavily on an expert witness affidavit written by Kenyon. This affidavit is online at the TalkOrigins website. It was entered into evidence in the Kitzmiller case as evidence that Kenyon was explicitly defending "creation science"—and advocating that it be given equal time in public schools and textbooks as the "only" alternative to evolution—while at the same time working on a public school textbook, which eventually became the first "intelligent design" book, Of Pandas and People. In 1987, in Edwards v. Aguillard the Supreme Court heard a case concerning a Louisiana Law that required "creation science" be taught on an equal basis with evolution in public schools. Anti-creationists argued that this was illegal on the basis that it violated the Establishment Clause of the US Constitution. Kenyon issued an affidavit in that case, stating his support for creationism, and defining it thus:

Salvinorin A induces prominent auditory phenomena and gating of audio-visual information at the perceptual threshold, coupled with unusual modifications of interoceptive awareness and body ownership that exhibit inverted-U-shaped dose-response relationship. Low to moderate doses enhance sensations and perceived body-safety, whereas high doses produce depersonalization, loss of body awareness, out-of-body experiences, and subjective feelings of existing in alternative spatial or dimensional realities, sometimes as objects or alternatively other living organisms. KOR activation also suppresses activity in sensory-integration regions, including parietal and temporal areas involved in body schema codification and multisensory binding, whilst simultaneously disrupting medial prefrontal cortex-mediated self-referential processing within the DMN. The claustrum is embedded within cortico-claustro-cortical loops that depend on maintained thalamic-cortical communication; consequently, thalamic KOR activation may disrupt claustral function indirectly through compromised afferent and efferent signaling rather than through direct local inhibition. Collectively, it is likely that KOR-mediated experiences of dimensionality alterations, synesthesia, and modified temporal perception represent emergent properties of disrupted hierarchical sensory integration at thalamic and cortical levels coupled with claustrum activity rather than direct consequences of that single region or modulation of its pathways.

=== Legal status === In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Nexviadyme, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Genzyme Europe BV. In August 2021, Genzyme Europe BV requested a re-examination. Avalglucosidase alfa was approved for medical use in the European Union in June 2022. The U.S. Food and Drug Administration (FDA) granted the application for avalglucosidase alfa fast track, priority review, breakthrough therapy, and orphan drug designations. The FDA granted the approval of Nexviazyme to Genzyme Corporation.

Sources: en.wikipedia.org

Frequently asked questions